Industry Supply
--Number of Drug Approval Numbers in the Industry
As of 2022, China*** has 156,711 domestic and foreign drug approval numbers, among which The number of domestic document numbers is 152,713, an increase of 2,692 from 2021; the number of imported registration certificate numbers is 2,998, a decrease of 1,630 from last year.
--Smooth fluctuations in the number of industry production enterprise licenses
According to the State Drug Administration, the number of China's drug production enterprise licenses will fluctuate steadily around 7,500 from 2011-2022, and in general, the drug production number of enterprises is relatively stable. By the end of 2022, the number of drug manufacturing licenses by provinces (autonomous regions and municipalities) was 7,974, an increase of 497 from 2021.
Industry Demand
--Industry Sales Revenue Approaching 1.8 Trillion Yuan
From 2014 to 2022, China's three major endpoints and six markets for drug sales show a fluctuating upward trend, of which sales declined in 2020 and increased in the remaining years.In 2022, China's three major terminal six markets drug sales approaching 1.8 trillion yuan, an increase of about 1% year-on-year.
--New product sales revenue increased dramatically
With the overall new product R & D expenditure in the growth trend, China's biopharmaceutical industry during the period of 2016-2021, the scale of sales of new products has been a relatively fast growth trend. 2021, China's The sales revenue of new products in the biopharmaceutical industry increased by more than 250% year-on-year.In 2022, the scale of production and sales of new products in China's biopharmaceutical industry will be about 450.7 billion yuan.
Industry scale fluctuates and grows
From 2016 to 2022, the market scale of China's biopharmaceutical industry showed a fluctuating growth trend, and the scale of the biopharmaceutical industry declined in 2020 due to the impact of epidemics.In 2022, the market scale of China's biopharmaceutical industry reaches 1.87 trillion yuan.
Industry growth point: the international environment and domestic policy double good
Overall, a large part of China's biomedical technology currently remains in the scientific research and has not been effectively converted into productive capacity, which not only wastes a lot of resources, but also makes China's production practices to keep up with the research and development, resulting in the production of lagging conditions This not only wastes a lot of resources, but also makes China's production practice can not keep up with R & D, resulting in production lag. Under the background of favorable international environment and domestic policy support, China's biopharmaceutical industry still has huge development space.
For more research and analysis of this industry, please refer to the Prospect Industry Research Institute's "China Biomedical Industry Development Outlook Forecast and Investment Strategy Planning Analysis Report".